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Objective: The aim of this study was to evaluate the therapeutic response and complications of high-
intensity focused ultrasound for patients with localized prostate cancer.
Materials and Methods: We evaluated the clinical outcomes of 29 patients who received high-intensity
focused ultrasound as ﬁrst-line treatment for localized prostate cancer at our hospital from October
2010 to March 2016. Biochemical recurrence was deﬁned, according to the Stuttgart deﬁnition of
biochemical failure, as the prostate-speciﬁc antigen nadir plus 1.2 ng/mL. Prostate-speciﬁc antigen levels
and complications were recorded during regular follow-up.
Results: The mean follow-up period was 24.6 months. Six patients experienced biochemical recurrence
(20.68%). Disease progression was noted in six patients (20.68%), and salvage therapy was performed in
these patients. The 24.6-month cancer-speciﬁc survival rate was 100%. No severe complications were
reported.
Conclusion: High-intensity focused ultrasound is an alternative therapy for patients with localized
prostate cancer. In combination with preceding transurethral resection of the prostate, this treatment
shows promise in disease control with a low complication rate in short-term follow-up.
Copyright © 2016, Taiwan Urological Association. Published by Elsevier Taiwan LLC. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Prostate cancer was among the most frequently diagnosed tu-
mors among men in the United States in 2014.1 For patients with
localized disease, radical surgery including radical prostatectomy,
laparoscopic prostatectomy, or robotic-assisted radical prostatec-
tomy should be considered. Brachytherapy and external beam ra-
diation therapy are regarded as equally effective against localized
disease.2 However, these therapeutic approaches can result in
complications that can affect the quality of life.3 Patients with
multiple comorbidities are at high risk when undergoing radical
surgery. Consequently, the need for minimally invasive treatments
for localized prostate cancer, such as high-intensity focused ultra-
sound (HIFU) and cryotherapy, has increased in recent years.tment of Surgery, Tri-Service
No. 325, Sec. 2, Chenggong
).
ociation. Published by Elsevier Ta
et al., Single session of high-
experience, Urological SciencHyperthermia and cavitation are the two major mechanisms by
which HIFU can be used to treat localized prostate cancer.4 The
therapeutic effect of HIFU on human prostate cancer in vivo was
ﬁrst described in 1995.5 Study results showed that HIFU was an
effective, minimally invasive treatment for prostate cancer. Over
time, as technology improved, HIFU became a more accessible
therapeutic option for patients with localized prostate cancer.
Nonetheless, HIFU is not routinely recommended owing to a lack of
prospective, randomized, and controlled clinical trials with sufﬁ-
cient follow-up in the medical literature.6,7
Here, we present a single-center experience of 29 patients with
localized prostate cancer treated with HIFU between October 2010
and March 2016. Oncological outcomes and complications are also
discussed in relation to the literature.2. Materials and methods
This study involved 29 patients with localized prostate cancer
who received HIFU as ﬁrst-line therapy at Tri-Service Generaliwan LLC. This is an open access article under the CC BY-NC-ND license (http://
intensity focused ultrasound therapy for the management of organ-
e (2016), http://dx.doi.org/10.1016/j.urols.2016.09.002
Table 1
Characteristics of 29 patients with localized prostate.
Age (y) 68.1 (59e82)
PSA (ng/mL) 10.3 (0.5e31.5)
Clinical stage
cT1a 1 (3.44)
cT1b 3 (10.34)
cT1c 19 (65.5)
cT2a 1 (3.44)
cT2b 1 (3.44)
cT2c 4 (13.79)
TURP before HIFU
No 2 (6.89)
Yes 27 (93.1)
Gleason score
6 16 (55.17)
7 12 (41.37)
>7 1 (3.44)
NCCN risk groups
Low risk 11 (37.93)
Intermediate risk 14 (48.27)
High risk 4 (13.79)
Median prostate volume (mL) 27.15 (9.32e59.6)
Data are presented as n (%) or mean (range), unless otherwise indicated.
HIFU¼ high-intensity focused ultrasound; NCCN¼ national comprehensive
cancer network; PSA¼ prostate-speciﬁc antigen; TURP¼ transurethral resection
of the prostate.
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General characteristics, prostate-speciﬁc antigen (PSA) levels, and
clinical staging data were collected prospectively from patient
medical records. We established the following inclusion criteria:
localized prostate cancer, clinical stages T1N0M0eT2N0M0, no
previous hormone therapy (HT) or radiation therapy, and lack of
suitability for radical prostatectomy due to multiple comorbidities
or high risk for surgical complications. Our exclusion criteria
included locally advanced disease, metastatic disease, and rectal
wall disease. The diagnosis of prostate cancer was established by
transrectal ultrasound (TRUS)-guided needle biopsy of the prostate.
Clinical staging was determined on the basis of magnetic resonance
imaging of the pelvis and awhole-body bone scan. According to the
results of clinical stage, Gleason score, and PSA levels, patients were
classiﬁed into risk groups according to the National Comprehensive
Cancer Network recurrence risk stratiﬁcation guidelines. Patients
ﬁrst underwent transurethral resection of the prostate (TURP), and
then returned 4 weeks later to receive HIFU therapy.
The Ablatherm HIFU device (EDAP TMS, Vaulx-en-Velin, France)
is composed of a treatment module, a control module, and a probe
with both image and treatment transducers. After the administra-
tion of general or spinal anesthesia, the patient is transferred to the
treatment module and placed in the right lateral decubitus posi-
tion. The probe is then introduced into the rectum for a pretreat-
ment evaluation using an ultrasound image. The prostate cancer
will be observed as a hypoechoic lesion under the image transducer
before treatment. Depending on the tumor location and volume, a
personalized therapeutic strategy is designed by adjusting the pa-
rameters of the control module. Using the HIFU system, the treat-
ment process may be performed automatically. During HIFU
therapy, a hypoechoic lesion will change to a hyperechoic lesion in
which we can evaluate the degree of destruction in real time.8
Following whole-gland ablation with HIFU, suprapubic cys-
tostomy was performed in the study patients. Two days later, the
Foley catheter was removed, and patients were discharged. Follow-
up was arranged by our outpatient department. The suprapubic
cystostomy tube was removed 1 week after discharge during the
ﬁrst outpatient department visit. Patients were subsequently seen
everymonth, and their PSA levels were checked every othermonth.
The PSA nadir was deﬁned as the lowest level during follow-up.
Oncological outcomes were assessed on the basis of biochemical
failure and cancer-speciﬁc survival rate. The Stuttgart deﬁnition of
biochemical failurewas used to deﬁne biochemical recurrence (PSA
nadir plus 1.2 ng/mL).9 Repeated TRUS-guided needle biopsy was
recommended if biochemical failure developed. Salvage therapy
would be arranged in the event of biochemical recurrence even if
the result of TRUS-guided needle biopsy of the prostate was
negative. HIFU-related complications were also recorded during
outpatient department follow-up.Table 2
Postoperative outcomes and complications.
Mean time to PSA nadir (d) 57.96
PSA nadir (ng/mL) 0.2116
Undetectable (<0.04 ng/mL) 16
Detectable (ng/mL) 13
<1 10
>1 3
Secondary biopsy 5
Complications
Urinary tract infection 6 (20.6)
Urethral stricture 8 (27.58)
Erectile dysfunction 7 (24.13)
Bladder neck contracture 7(24.13)
Data are presented as n or n (%).
PSA¼ prostate-speciﬁc antigen.3. Results
3.1. Patients
This study included 29 patients diagnosed with localized pros-
tate cancer who received HIFU therapy at Tri-Service General
Hospital between October 2010 and March 2016. Characteristics of
the 29 patients with localized prostate are shown in Table 1. The
mean age was 68.1 years, and the mean follow-up duration was
24.6 months. Themean PSA level was 10.3 ng/mL. The predominant
clinical stages were T1cN0M0 (19 patients, 65.5%) and T2cN0M0 (4
patients, 13.79%). Almost all patients underwent TURP (27 patients,
93.1%) before HIFU therapy. According to National Comprehensive
Cancer Network guidelines, the majority of patients were classiﬁedPlease cite this article in press as: Juho Y-C, et al., Single session of high-
conﬁned prostate cancer: A single-institute experience, Urological Sciencto be at intermediate risk (14 patients, 48.27%). However, four pa-
tients were lost to follow-up due to relocation.
3.2. Treatment
Patients were treated with the Ablatherm HIFU device (EDAP
TMS) between October 2010 and March 2016. Most patients un-
derwent a single HIFU session, although three patients (10.34%)
underwent a second HIFU session due to biochemical failure or
biopsy-proven malignancy.
3.3. Oncological outcomes
Postoperative outcomes and complications are shown in Table 2.
The mean PSA nadir was 0.21 ng/mL and was achieved within a
mean of 1.9 months after HIFU therapy. Undetectable PSA levels
were noted in 16 patients. Only three patients had PSA nadir levels
greater than 1 ng/mL. One of these patients displayed biochemical
recurrence 6 months later and underwent TRUS-guided needle
biopsy that revealed adenocarcinoma of the prostate. Secondary
HIFU was arranged immediately for disease control, but owing to
progression of the PSA level, salvage radiation therapy was per-
formed. The second patient with a PSA nadir of > 1 ng/mL under-
went HT for bone metastasis. The third patient experiencedintensity focused ultrasound therapy for the management of organ-
e (2016), http://dx.doi.org/10.1016/j.urols.2016.09.002
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The cancer-speciﬁc survival rate was 100% and the metastasis-free
survival rate was 96.55%.
3.4. Safety
During the operation, no immediate complications developed in
any patients. Postoperative complications included urinary tract
infection, urethral stricture, erectile dysfunction, and bladder neck
contracture. Themost common complicationwas urethral stricture.
Prostatitis was observed in only one patient who did not undergo
preceding TURP.
4. Discussion
Although HIFU has been used to treat prostate cancer for more
than 20 years,5 the role of HIFU in the treatment of localized
prostate cancer is still controversial. According to the European
Association of Urology and American Urological Association
guidelines, HIFU has therapeutic effects in localized prostate cancer.
However, this therapy has not been routinely recommended, owing
to the lack of prospective and randomized controlled trials with
long-term follow-up conducted until recently.6,7
Table 3 shows the ﬁndings of our study and the recent studies
related to the results of long-term follow-up after HIFU treatment
for prostate cancer. Adenocarcinoma of the prostate was proved by
TRUS-guided needle biopsy. No nodal or distant metastasis was
found on image evaluation. The initial mean PSA level was< 15 ng/
mL. Neoadjuvant HT was used in 29e44% of men, and preceding
TURP was used in 20e93% of men. The PSA nadir (0.03e0.55 ng/
mL) was achieved within 5 months after primary HIFU therapy. The
biochemical recurrence rate was deﬁned using various criteria.
These studies also showed excellent cancer-speciﬁc survival rates
of 90e100% on long-term follow-up. In our study, similar onco-
logical outcomes including low biochemical recurrence (20.68%)
and high cancer-speciﬁc survival rates (100%) were also noted.
However, the short follow-up period and the small number of cases
are the major limitations of the current study.
Owing to the limited evidence regarding neoadjuvant HT before
HIFU for localized prostate cancer,6,7 we did not perform this
therapy before HIFU in all patients. Komura et al10 demonstrated
that neoadjuvant HT followed by HIFU renders cancer manageable
by reducing the prostate volume and resulting in more rapid
achievement of the PSA nadir. By contrast, the use of neoadjuvant
HT did not result in any signiﬁcant difference in the 5-year
biochemical recurrence-free survival rate in a study by Ganzer
et al.11 However, currently, the use of neoadjuvant HT before HIFU
for localized prostate cancer seems safe and feasible.
HIFU therapy is not suitable for large-volume localized prostate
cancer because of the short therapeutic length of about
19e26 mm.8 In order to increase the application of HIFU therapy in
prostate cancer, preceding TURP has been performed since 2000,12Table 3
Case series of HIFU for localized prostate cancer and outcome.
MFSR (%) 96.55 (25 mo) 99.4 (5 y) 70 (10 y)
CSSR (%) 100 (25 mo) 100 (5 y) 90 (10 y)
Biochemical failure (%) 20.68 (Stuttgart) 25.7 (Stuttgart) 46 (Stuttga
Nadir/time to nadir 0.21/1.9 mo 0.03/2.5 mo 0.55/4 mo
PSA 10.3 (mean) 7.7 (median) 12.1 (mean
Follow-up (mo) 24.6 (mean) 43 (median) 94 (median
Clinical stage T1N0M0eT2N0M0 T1N0M0eT2N0M0 T1N0M0eT
Mean age (y) 68.1 68.3 76.1
Patient No. 29 171 110
Case series Our series Komura et al10 Limani et a
CSSR¼ cancer-speciﬁc survival rate; HIFU¼ high-intensity focused ultrasound; MFSR¼m
Please cite this article in press as: Juho Y-C, et al., Single session of high-
conﬁned prostate cancer: A single-institute experience, Urological Sciencand Rebillard et al13 showed the beneﬁcial effect of this therapy in
shrinking prostate volume, removing calciﬁcation, decreasing the
catheterization period, and reducing complications. In our series,
only two patients did not receive preceding TURP owing to a
relatively small prostate volume. All patients experienced bladder
outlet obstruction and underwent surgical intervention. Routine
preceding TURP may be considered not only for the prevention of
complications, but also for whole-gland therapy.
The PSA nadir has been described as a predictive factor for
oncological failure of localized prostate cancer after HIFU ther-
apy.12,14 In our study, a PSA nadir of > 1 ng/mL was found in three
patients. Two of these patients were at high risk, and the other
patient was at intermediate risk. They all received salvage treat-
ment and experienced promising disease control. Thüroff and
Chaussy12 demonstrated that the PSA nadir is the greatest predictor
of biochemical failure. In their study, the PSA nadir was obtained at
a mean of 2.1 months after treatment, which is standard following
tumor ablation. If the nadir is < 0.3 ng/mL, the 5-year biochemical
disease-free survival rate is 94%. Crouzet et al15 showed similar
results in that the 5-year biochemical disease-free survival rate was
91% in patients with a PSA nadir of < 0.3 ng/mL. Their study also
showed that the cut-off value for PSA levels after HIFU therapy for
early control biopsy was 0.3 ng/mL in most hospitals. However, the
cutoff value of PSA nadirs for predicting treatment failure remains
controversial.16
Salvage treatment after HIFU therapy should be considered in
patients with local recurrence or biochemical failure according to
the results of prostate biopsy, bone scan, and magnetic resonance
imaging.17 Ganzer et al11 performed HIFU therapy in 538 patients
with localized prostate cancer. Ninety-seven patients (18%)
received salvage therapy including HT, radiation therapy, chemo-
therapy, and radical prostatectomy. Signiﬁcantly fewer patients at
low risk underwent salvage therapy. We also used salvage therapy
for patients with disease progression. Table 4 shows the effects of
salvage therapy for disease recurrence in our series. Secondary
HIFU for local recurrence and HT for bone metastasis showed
promising results for disease control. However, three patients
experienced PSA progression without positive ﬁndings of mag-
netic resonance imaging, bone scan, and prostate biopsy. Man-
agement of biochemical failure in prostate cancer is controversial,
and about one-third of these patients will develop distal metas-
tasis eventually.18 Androgen deprivation therapy was prescribed,
and acceptable disease control with decreasing PSA levels was
found.
Table 5 shows the complications after HIFU therapy for localized
prostate cancer in our study and in recent studies. Complications
including urinary retention, bladder neck stenosis, urethral stric-
ture, chronic pelvic discomfort, and epididymitis have been
described.8 Along with the improvements in the HIFU device and
the utility of preceding TURP, a decreasing incidence of complica-
tions has also been noted.13 For example, rectal ﬁstulas are rarely
found after integrating the use of imaging with HIFU devices.12 In>95 (10 y) 95 (10 y) 94 (10 y)
>95 (10 y) 99 (10 y) 97 (10 y)
rt) <39 (Phoenix) N/A 21.1 (Phoenix)
0.4/20 wk 0.1/2.1 mo 0.14/7.9 wk
) 11.2 (mean) 9.9 (mean) 7.7 (median)
) 97 (mean) 63 (mean) 78 (median)
2N0M0 T1N0M0eT3N0M0 T1N0M0eT2N0M0 T1N0M0eT3N0M0
67.7 68.4 71
538 704 1002
l14 Ganzer et al11 Thüroff & Chaussy12 Crouzet et al14
etastasis free survival rate; PSA¼ prostate-speciﬁc antigen.
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Table 4
Salvage therapy for disease recurrence after HIFU treatment in our series.
Patient
No.
PSA
Gleason score
Clinical stage
PSA nadir/max. PSA
following HIFU
Evaluation Treatment Latest
PSA
1 26.9
3þ 4
T1cN0M0
1.09/2.59 MRI ()
Bone scan ()
Biopsy (þ)
HIFU
RT
<0.04
2 11.4
5þ 5
T2cN0M0
1.57/2.21 MRI (þ)
Bone scan (þ)
Biopsy ()
HT <0.04
3 10.63
3þ 4
T1cN0M0
1.14/2.34 MRI ()
Bone scan ()
Biopsy ()
HIFU 0.1
4 15
3þ 4
T2cN0M0
<0.04/1.85 MRI (þ)
Bone scan ()
Biopsy ()
HIFU 0.85
5 3.9
3þ 4
T1cN0M0
0.1/1.34 MRI ()
Bone scan ()
Biopsy ()
HT 0.24
6 7.7
3þ 4
T1cN0M0
0.73/1.91 MRI ()
Bone scan ()
HT 1.34
HIFU¼ high-intensity focused ultrasound; HT¼ hormone therapy; MRI¼magnetic
resonance imaging; PSA¼ prostate-speciﬁc antigen; RT¼ radiation therapy.
Table 5
Case series of HIFU for localized prostate cancer considering the complications.
Case series BOO (%) SUI (%) Impotency (%) Fistula (%) UTI (%)
Our series 48.27 17.24 24.13 0 20.6
Blana et al9 11.7 5.8 52.7 0.7 4.8
Limani et al14 21 11 30.8 0.9 18
Ganzer et al11 28.3 20.1 35 0.7 10.2
Thüroff & Chaussy12 21.4 3.26 45 0.28 2.1
Crouzet et al14 16.6 23.7 57.7 0.4 3.9
BOO¼ bladder outlet obstruction; HIFU¼ high-intensity focused ultrasound;
SUI¼ stress urinary incontinence; UTI¼ urinary tract infection.
Y.-C. Juho et al. / Urological Science xxx (2016) 1e44our study, no rectal ﬁstulas were observed in the 29 patients. To
avoid acute urinary retention and decrease the catheterization
period, suprapubic cystostomywas performed in all patients before
HIFU therapy.
This study focused on the results of HIFU treatment of localized
prostate cancer. A low biochemical recurrence rate (20.68%),
acceptable complication rates, and a high cancer-speciﬁc survival
rate (100%) were obtained. However, the short follow-up period of
24.6 months and the small number of cases are limitations of this
study. Therefore, long-term beneﬁts of HIFU for localized prostate
cancer should be evaluated in further well-designed randomized
controlled trials.Please cite this article in press as: Juho Y-C, et al., Single session of high-
conﬁned prostate cancer: A single-institute experience, Urological SciencConﬂicts of interest
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